AU2001285018A1 - Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer - Google Patents
Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancerInfo
- Publication number
- AU2001285018A1 AU2001285018A1 AU2001285018A AU8501801A AU2001285018A1 AU 2001285018 A1 AU2001285018 A1 AU 2001285018A1 AU 2001285018 A AU2001285018 A AU 2001285018A AU 8501801 A AU8501801 A AU 8501801A AU 2001285018 A1 AU2001285018 A1 AU 2001285018A1
- Authority
- AU
- Australia
- Prior art keywords
- catrf2e11
- cancer
- useful
- detection
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22632900P | 2000-08-17 | 2000-08-17 | |
| US60/226,329 | 2000-08-17 | ||
| PCT/US2001/025782 WO2002014361A2 (en) | 2000-08-17 | 2001-08-17 | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001285018A1 true AU2001285018A1 (en) | 2002-02-25 |
Family
ID=22848496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001285018A Abandoned AU2001285018A1 (en) | 2000-08-17 | 2001-08-17 | Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001285018A1 (en) |
| WO (1) | WO2002014361A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60134178D1 (en) * | 2000-07-28 | 2008-07-03 | Ulrich Wissenbach | TRP8 CANCER MARKER |
| CA2512392A1 (en) * | 2003-01-08 | 2004-07-29 | Toudai Tlo, Ltd. | Human calcium transporter 1 gene, screening method of calcium absorption regulating factor, and calcium absorption regulating factor |
| EP2518149B1 (en) | 2006-02-22 | 2015-12-16 | International Institute of Cancer Immunology, Inc. | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
| US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
| EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
| WO2015171610A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
| AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| WO2019105864A1 (en) | 2017-11-30 | 2019-06-06 | F. Hoffmann-La Roche Ag | B-cell cultivation method |
| WO2022120423A1 (en) * | 2020-12-08 | 2022-06-16 | James Cook University | Peptides and uses thereof |
-
2001
- 2001-08-17 AU AU2001285018A patent/AU2001285018A1/en not_active Abandoned
- 2001-08-17 WO PCT/US2001/025782 patent/WO2002014361A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002014361A2 (en) | 2002-02-21 |
| WO2002014361A3 (en) | 2003-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002318112B2 (en) | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers | |
| SI1576170T1 (en) | Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer | |
| WO2003087306A8 (en) | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer | |
| EP1517606A4 (en) | Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer | |
| AU2002337696A1 (en) | Detection of tumor rna in plasma and serum | |
| EP1622571A4 (en) | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer | |
| AU3510200A (en) | Human dickkopf-related protein and nucleic acid molecules and uses therefor | |
| AU2002246808A1 (en) | Human nucleic acids and polypeptides and methods of use thereof | |
| PT1537140E (en) | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer | |
| AU2002257050A1 (en) | Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer | |
| AU2002218269A1 (en) | Proteins and dna sequences underlying these proteins used for treating inflammations | |
| EP1590437A4 (en) | Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer | |
| AU2001285018A1 (en) | Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer | |
| AU2002258785A1 (en) | Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer | |
| AU2002246708A1 (en) | Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer | |
| AU2001251621A1 (en) | Gtp-binding protein useful in treatment and detection of cancer | |
| EP1539805A4 (en) | Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer | |
| AU2001286541A1 (en) | Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer | |
| AU2002254079A1 (en) | Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer | |
| AU2001249929A1 (en) | Fdrg proteins and nucleic acid molecules and uses therefor | |
| WO2003085121A9 (en) | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer | |
| AU2001266813A1 (en) | Human proteins and nucleic acids encoding same | |
| AU2001256977A1 (en) | Human sez6 nucleic acids and polypeptides | |
| AU2012244341A1 (en) | Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer | |
| AU2002305170A1 (en) | Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer |